Adverse events
| Placebo | Rivastigmine | |
|---|---|---|
| Serious adverse events | ||
| Worsening of the parkinsonian syndrome | 1 | 0 |
| Excessive drowsiness and headache | 1 | 0 |
| Sudden death due to previously undetected generalised cancer | 1 | 0 |
| Non-serious adverse events | ||
| Asthenia/drowsiness (transient in one case and permanent in two cases) | 0 | 3 |
| Faintness (transient in two cases and permanent in one case) | 0 | 3 |
| Transient worsening of painful dyskinesia | 0 | 1 |
| Transient urinary retention | 1 | 0 |
| Severe nightmares | 1 | 0 |
| Total number of adverse events | 5 | 7 |
The analyses were performed on the randomised population (16 patients in the rivastigmine group and 14 patients in the placebo group).